Skip to main content

Genomic Health Inks PGx Alliance with OncoMed

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market Wednesday that it will collaborate with OncoMed Pharmaceuticals in identifying biomarkers that can be applied to clinical development of certain OncoMed antibody cancer drugs.

OncoMed will provide Genomic Health with breast, prostate, colon, and lung tumor samples, and will include a subset of OncoMed's proprietary xenograft models derived from freshly resected human cancers. Genomic Health will use its next-generation sequencing capabilities to discover biomarkers that may help identify patients that are more likely to respond to cancer therapeutics that target the Notch, Wnt and other pathways critical to cancer stem cells.

"This collaboration supports our long-term vision and belief that molecular diagnostics are inherent for bringing quality, personalized care to all cancer patients from diagnosis through survivorship," Genomic Health Chief Medical Officer Steve Shak said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.